{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Gilead Sciences reports 2014 adjusted net income of $13.3 billion, or $8.09 per diluted share, up from $3.5 billion, or $2.04 per diluted share in 2013; reports selling $10.3 billion of new hepatitis C drug Sovaldi; sales of drug, which is priced at $1,00 per pill, have strained health plans, Medicaid and prison systems, putting it front and center amid debate over drug prices.", "type_of_material": "News", "word_count": "913", "lead_paragraph": "Global sales of Sovaldi brought it close to being the best-selling drug in the world in only its first year on the market.", "pub_date": "2015-02-04T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion", "print_headline": "Sales of New Hepatitis C Drug Soar to $10.3 Billion, Straining Budgets"}, "snippet": "Global sales of Sovaldi brought it close to being the best-selling drug in the world in only its first year on the market.", "multimedia": [{"height": 126, "url": "images/2015/02/04/business/04GILEAD/04GILEAD-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/02/04/business/04GILEAD/04GILEAD-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 567, "url": "images/2015/02/04/business/04GILEAD/04GILEAD-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "567", "xlarge": "images/2015/02/04/business/04GILEAD/04GILEAD-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/02/04/business/04GILEAD/04GILEAD-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/02/04/business/04GILEAD/04GILEAD-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/02/04/business/sales-of-sovaldi-new-gilead-hepatitis-c-drug-soar-to-10-3-billion.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Gilead Sciences Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Sovaldi (Drug)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Hepatitis", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Company Reports", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Harvoni (Drug)", "name": "subject"}], "blog": [], "_id": "54d1581938f0d86a52397ac6", "source": "The New York Times"}